{"title":"为什么合作是辉瑞和默克制药竞争对手在免疫肿瘤领域获得竞争优势的更好策略——分析两家公司的利益","authors":"Evgeniia Popova","doi":"10.2139/ssrn.3061160","DOIUrl":null,"url":null,"abstract":"Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.","PeriodicalId":191980,"journal":{"name":"IRPN: Innovation & Food & Drug Law & Policy (Sub-Topic)","volume":"83 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Why Cooperation is a Better Strategy to Achieve Competitive Advantage in Immuno-Oncology for Pharma Rivals Pfizer and Merck KGaA - Analyzing the Companies' Benefits\",\"authors\":\"Evgeniia Popova\",\"doi\":\"10.2139/ssrn.3061160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.\",\"PeriodicalId\":191980,\"journal\":{\"name\":\"IRPN: Innovation & Food & Drug Law & Policy (Sub-Topic)\",\"volume\":\"83 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IRPN: Innovation & Food & Drug Law & Policy (Sub-Topic)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3061160\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IRPN: Innovation & Food & Drug Law & Policy (Sub-Topic)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3061160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Why Cooperation is a Better Strategy to Achieve Competitive Advantage in Immuno-Oncology for Pharma Rivals Pfizer and Merck KGaA - Analyzing the Companies' Benefits
Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
